SCHEMBL5065670

SCHEMBL5065670

CC(C)(C)OC(=O)N1C(=O)[C@H](Cc2ccccc2)C[C@H]1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 8/20 0.49
KLK5 Q9Y337 7/20 0.46
PRSS1 P07477 3/20 0.44
PRSS2 P07478 3/20 0.44
PRSS3 P35030 3/20 0.44
PLA2G10 O15496 1/20 0.42
PLA2G5 P39877 1/20 0.42
STS P08842 1/20 0.42
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
P2RX7 Q99572 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
TSHR P16473 1/20 0.39
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31486428 1.00 KLK7 (0.49) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL8669568 1.00 KLK7 (0.49) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL7699900 0.93 KLK7 (0.43) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL8667026 0.92 KLK7 (0.48) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL7697794 0.88 KLK7 (0.39) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL7697791 0.88 KLK7 (0.39) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL30387086 0.88 KLK7 (0.45) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL22446555 0.88 KLK7 (0.45) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL12643706 0.88 KLK7 (0.45) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL31486524 0.88 KLK7 (0.45) KLK7KLK5PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076824-A1 modified glycinamides: Valine-alphahydroxy-glycinamide CHRONTECH PHARMA AB (SE) 2008-03-27 US disclosed
US-20080076824-A1 modified glycinamides: Valine-alphahydroxy-glycinamide CHRONTECH PHARMA AB (SE) 2008-03-27 US disclosed
US-20080076824-A1 modified glycinamides: Valine-alphahydroxy-glycinamide CHRONTECH PHARMA AB (SE) 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076824-A1 modified glycinamides: Valine-alphahydroxy-glycinamide GALE, ENGASE, UGGT1 KLK7 3643/4885KLK5 2461/4885PRSS1 718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.